Neurobehavioral assessment of hydroalcoholic extract of Trigonella foenum-graecum seeds in rodent models of Parkinson's disease

Pharmaceutical Biology

Volumn 51, Issue 5, 2013, Pages 550-557

  Gaur, Vaibhav ^a   Bodhankar, Subhash L ^a   Mohan, V ^b   Thakurdesai, Prasad A ^b  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b Indus Biotech Private Limited   (India)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine induced neurotoxicity; 6 hydroxydopamine lesions; Animal model of disease; Fenugreek; Neurodegenerative disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALCOHOL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CHOLINESTERASE; OXIDOPAMINE; TRIGONELLA FOENUM GRAECUM EXTRACT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG SCREENING; ENZYME INHIBITION; FENUGREEK; IN VITRO STUDY; IN VIVO STUDY; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSON DISEASE; PHYTOCHEMISTRY; PLANT SEED; RAT; SINGLE DRUG DOSE; SOLVENT EXTRACTION;

ADMINISTRATION, ORAL; ALKALOIDS; ANIMALS; ANTIPARKINSON AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PLANT EXTRACTS; RATS; RATS, WISTAR; SEEDS; TRIGONELLA;

ANIMALIA; FABACEAE; MUS; RATTUS; RODENTIA; TRIGONELLA FOENUM-GRAECUM;

EID: 84876590026     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2012.747547     Document Type: Article

References (46)

1. Annett LE, Rogers DC, Hernandez TD, Dunnett SB. (1992). Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain 115: 825-56.
2. Anonymous. (1983). New hope for Parkinsonism. Chemical Week 27 April 1983, 331.
3. Anuradha CV, Ravikumar P. (2001). Restoration on tissue antioxidants by fenugreek seeds (Trigonella foenum graecum) in alloxan-diabetic rats. Indian J Physiol Pharmacol 45: 408-20. (Pubitemid 33026893)
4. Beal MF. (2001). Experimental models of Parkinson's disease. Nat Rev Neurosci 2: 325-534.
5. Berglund T. (1994). Nicotinamide, a missing link in the early stress response in eukaryotic cells: A hypothesis with special reference to oxidative stress in plants. FEBS Lett 351: 145-9. (Pubitemid 24277257)
6. Cotzias GC, Papavasiliou PS, Gellene R. (1969). Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 280: 337-45.
7. Deumens R, Blokland A, Prickaerts J. (2002). Modeling Parkinson's disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175: 303-17. (Pubitemid 34634286)
8. Devasena T, Menon VP. (2002). Enhancement of circulatory antioxidants by fenugreek during 1,2-dimethylhydrazine-induced rat colon carcinogenesis. J Biochem Mol Biol Biophys 6: 289-92.
9. Devasena T, Menon VP. (2007). Fenugreek seeds modulate 1,2-dimethylhydrazine-induced hepatic oxidative stress during colon carcinogenesis. Ital J Biochem 56: 28-34. (Pubitemid 46658111)
10. Dunnett SB, Bjorklund A. (1999). Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399: A32-9.
11. Duvoisin RC. (1976). Parkinsonism: animal analogues of the human disorder. Res Publ Assoc Res Nerv Ment Dis 55: 293-303.
12. Finnegan KT, Irwin I, Delanney LE, et al. (1987). 1,2,3,6-Tetrahydro-1- methyl-4-(methylpyrrol-2-yl)pyridine: studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Pharmacol Exp Ther 242: 1144-51. (Pubitemid 17156565)
13. Henchcliffe C, Beal MF. (2008). Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neuro 4: 600-9.
14. Hong BN, Yi TH, Park R, et al. (2008). Coffee improves auditory neuropathy in diabetic mice. Neurosci Lett 441: 302-6.
15. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. (1995). Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4: 257-69.
16. Javitch JA, Snyder SH. (1984). Uptake of MPP(\+) by dopamine neurons explains selectivity of Parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol 106: 455-6. (Pubitemid 15210642)
17. Kaviarasan S, Ramamurty N, Gunasekaran P, et al. (2006). Fenugreek (Trigonella foenum graecum) seed extract prevents ethanolinduced toxicity and apoptosis in Chang liver cells. Alcohol Alcohol 41: 267-73.
18. Markham CH, Diamond SG. (1981). Evidence to support early levodopa therapy in Parkinson disease. Neurology 31: 125-31. (Pubitemid 11137587)
19. Mattila PM, Rinne JO, Helenius H, Roytta M. (1999). Neuritic degeneration in the hippocampus and amygdala in Parkinson's disease in relation to Alzheimer pathology. Acta Neuropathol (Berl) 98: 157-64. (Pubitemid 29355548)
20. McCall RB, Lookingland KJ, Bedard PJ, Huff RM. (2005). Sumanirole, a highly dopamine D2-selective receptor agonist: In vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease. J Pharmacol Exp Ther 314: 1248-56. (Pubitemid 41205991)
21. Meissner WG, Frasier M, Gasser T, et al. (2011). Priorities in Parkinson's disease research. Nat Rev Drug Discov 10: 377-93.
22. Mishkinsky J, Joseph B, Sulman FG. (1967). Hypoglycaemic effect of trigonelline. Lancet 2: 1311-12.
23. Nadkarni AK. (1990). The Indian Materia Medica. Bombay, India: Popular Prakashan Pvt Ltd.
24. Nayak L, Henchcliffe C. (2008). Rasagiline in treatment of Parkinson's disease. Neuropsychiatr Dis Treat 4: 23-32.
25. Nicklas WJ, Vyas I, Heikkila RE. (1985). Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36: 2503-8. (Pubitemid 15072756)
26. Papapetropoulos S, Basel M, Mash DC. (2007). Dopaminergic innervation of the human striatum in Parkinson's disease. Mov Disord 22: 286-8. (Pubitemid 46374785)
27. Paxinos G, Watson C. (2007). The Rat Brain in Stereotaxic Coordinates. 6th ed. Amsterdam, The Netherlands: Elsevier.
28. Pellegrino LJ, Pellegrino AS, Cushman AJ. (1979). A Stereotaxic Atlas of the Rat Brain. 2nd ed. New York, NY: Plenum Press.
29. Petropoulos GA. (2002). Fenugreek: The Genus Trigonella. New York, NY: Taylor and Francis.
30. Preet A, Gupta BL, Siddiqui MR, et al. (2005). Restoration of ultrastructural and biochemical changes in alloxan-induced diabetic rat sciatic nerve on treatment with Na3VO4 and Trigonella-a promising antidiabetic agent. Mol Cell Biochem 278: 21-31. (Pubitemid 41418916)
31. Ricaurte GA, Irwin I, Forno LS, et al. (1987). Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res 403: 43-51. (Pubitemid 17009738)
32. Ruberg M, Scherman D, Javoy-Agid F, Agid Y. (1995). Dopamine denervation, age of onset, and Parkinson's disease. Neurology 45: 392.
33. Saravanan R, Pari L. (2005). Antihyperlipidemic and antiperoxidative effect of diasulin, a polyherbal formulation in alloxan induced hyperglycemic rats. BMC Complement Altern Med 5: 1-8.
34. Schober A. (2004). Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318: 215-24. (Pubitemid 39366054)
35. Shah S, Bodhankar SL, Badole SL, et al. (2006). Effect of trigonelline: An active compound from Trigonella foenum graecum Linn. in alloxan induced diabetes in mice. J Cell Tissue Res 6: 585-90.
36. Silva MA, Mattern C, Hacker R, et al. (1997). Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: On the role of benserazide pretreatment. Synapse 27: 294-302. (Pubitemid 27479467)
37. Takeuchi H, Takahashi R. (2007). Pathogenesis of Parkinson disease. Nippon Ronen Igakkai Zasshi 44: 415-21.
38. Tohda C, Kuboyama T, Komatsu K. (2005). Search for natural products related to regeneration of the neuronal network. NeuroSignals 14: 34-45. (Pubitemid 40868982)
39. Tohda C, Nakamura N, Komatsu K, Hattori M. (1999). Trigonellineinduced neurite outgrowth in human neuroblastoma SK-N-SH cells. Biol Pharm Bull 22: 679-82. (Pubitemid 29361698)
40. Tuite P, Riss J. (2003). Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin Investig Drugs 12: 1335-52. (Pubitemid 36949693)
41. Ungerstedt U. (1971a). Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367: 95-122.
42. Ungerstedt U. (1971b). Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand Suppl 367: 49-68.
43. Urban P, Andersen JK, Hsu HP, Pompon D. (1991). Comparative membrane locations and activities of human monoamine oxidases expressed in yeast. FEBS Lett 286: 142-6.
44. Yen WJ, Wang BS, Chang LW, Duh PD. (2005). Antioxidant properties of roasted coffee residues. J Agric Food Chem 53: 2658-63.
45. Youdim MB, Finberg JP. (1991). New directions in monoamine oxidase A and B selective inhibitors and substrates. Biochem Pharmacol 41: 155-62.
46. Yuyama S, Suzuki T. (1985). Isolation and identification of N1-methylnicotinic acid (trigonelline) from rat urine. J Nutr Sci Vitaminol (Tokyo) 31: 157-67.